Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Core Insights - Coherus BioSciences, Inc. will release its first quarter 2025 financial results on May 12, 2025, after market close [1] - A conference call and webcast will be held at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] - The press release and related materials will be available on the company's investor website prior to the conference call [3][4] Company Overview - Coherus is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a growing revenue stream [6] - The company has a promising pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [6] - Coherus aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with its pipeline candidates and partners [6] Pipeline Details - Coherus' oncology pipeline features multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is currently in Phase 1 studies for advanced solid tumors, including head and neck squamous cell carcinoma and gastric cancer [7] - Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma [7]